Effects of etybenzatropine and diazepam on levodopa‐induced diphasic dyskinesias in Parkinson's disease
Identifieur interne : 000670 ( France/Analysis ); précédent : 000669; suivant : 000671Effects of etybenzatropine and diazepam on levodopa‐induced diphasic dyskinesias in Parkinson's disease
Auteurs : Emmanuelle Pourcher [France] ; Anne-Marie Bonnet [France] ; John Kefalos [France] ; Bruno Dubois [France] ; Agid [France]Source :
- Movement Disorders [ 0885-3185 ] ; 1989.
Descripteurs français
- Pascal (Inist)
- Antagoniste, Anticonvulsivant, Benzodiazépine dérivé, Chimiothérapie, Diazépam, Dopa, Dyskinésie, Etybenzatropine, Homme, Interaction médicamenteuse, Parkinson maladie, Prévention, Psychotrope, Récepteur cholinergique, Système nerveux pathologie, Toxicité, Traitement, Voie intramusculaire, Voie intraveineuse.
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Antagonist, Anticonvulsant, Benzodiazepine derivatives, Chemotherapy, Cholinergic receptor, Diazepam, Diazepam (therapeutic use), Dopa, Drug interaction, Dyskinesia, Dyskinesias, Etybenzatropine, Human, Humans, Intramuscular administration, Intravenous administration, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Middle Aged, Movement Disorders (chemically induced), Movement Disorders (drug therapy), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's Disease, Pilot Projects, Prevention, Psychotropic, Toxicity, Treatment, Tropanes (therapeutic use).
- MESH :
- chemical , adverse effects : Levodopa.
- chemical , therapeutic use : Diazepam, Levodopa, Tropanes.
- chemically induced : Movement Disorders.
- drug therapy : Movement Disorders, Parkinson Disease.
- Humans, Middle Aged, Pilot Projects.
Abstract
Levodopa‐induced onset and end‐of‐dose dyskinesia are rare but disabling disorders. Although they can be attenuated by increasing and dividing the daily dose of levodopa, this does not constitute a therapeutic approach. In this pilot study, etybenzatropine, an anticholinergic drug, and diazepam, a selective benzodiazepine, were administered in addition to a single dose of levodopa in nine patients with Parkinson's disease. Both drugs tended to decrease the severity and the duration of onset and end‐of‐dose dyskinesia, and to increase the duration of action of levodopa on parkinsonian symptoms.
Url:
DOI: 10.1002/mds.870040301
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003466
- to stream Istex, to step Curation: 003466
- to stream Istex, to step Checkpoint: 004490
- to stream PubMed, to step Corpus: 004F71
- to stream PubMed, to step Curation: 004F71
- to stream PubMed, to step Checkpoint: 004F88
- to stream Ncbi, to step Merge: 004537
- to stream Ncbi, to step Curation: 004537
- to stream Ncbi, to step Checkpoint: 004537
- to stream Main, to step Merge: 009813
- to stream PascalFrancis, to step Corpus: 003A18
- to stream PascalFrancis, to step Curation: 002E07
- to stream PascalFrancis, to step Checkpoint: 003A07
- to stream Main, to step Merge: 009869
- to stream Main, to step Curation: 006460
- to stream Main, to step Exploration: 006460
- to stream France, to step Extraction: 000670
Links to Exploration step
ISTEX:A0A1EF877A89AD91DC3BFBC1A4B1A1C73054D518Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of etybenzatropine and diazepam on levodopa‐induced diphasic dyskinesias in Parkinson's disease</title><author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name></author><author><name sortKey="Bonnet, Anne Arie" sort="Bonnet, Anne Arie" uniqKey="Bonnet A" first="Anne-Marie" last="Bonnet">Anne-Marie Bonnet</name></author><author><name sortKey="Kefalos, John" sort="Kefalos, John" uniqKey="Kefalos J" first="John" last="Kefalos">John Kefalos</name></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name></author><author><name sortKey="Agid" sort="Agid" uniqKey="Agid" last="Agid">Agid</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A0A1EF877A89AD91DC3BFBC1A4B1A1C73054D518</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1002/mds.870040301</idno><idno type="url">https://api.istex.fr/document/A0A1EF877A89AD91DC3BFBC1A4B1A1C73054D518/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003466</idno><idno type="wicri:Area/Istex/Curation">003466</idno><idno type="wicri:Area/Istex/Checkpoint">004490</idno><idno type="wicri:doubleKey">0885-3185:1989:Pourcher E:effects:of:etybenzatropine</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2779590</idno><idno type="wicri:Area/PubMed/Corpus">004F71</idno><idno type="wicri:Area/PubMed/Curation">004F71</idno><idno type="wicri:Area/PubMed/Checkpoint">004F88</idno><idno type="wicri:Area/Ncbi/Merge">004537</idno><idno type="wicri:Area/Ncbi/Curation">004537</idno><idno type="wicri:Area/Ncbi/Checkpoint">004537</idno><idno type="wicri:doubleKey">0885-3185:1989:Pourcher E:effects:of:etybenzatropine</idno><idno type="wicri:Area/Main/Merge">009813</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:90-0108086</idno><idno type="wicri:Area/PascalFrancis/Corpus">003A18</idno><idno type="wicri:Area/PascalFrancis/Curation">002E07</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003A07</idno><idno type="wicri:doubleKey">0885-3185:1989:Pourcher E:effects:of:etybenzatropine</idno><idno type="wicri:Area/Main/Merge">009869</idno><idno type="wicri:Area/Main/Curation">006460</idno><idno type="wicri:Area/Main/Exploration">006460</idno><idno type="wicri:Area/France/Extraction">000670</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of etybenzatropine and diazepam on levodopa‐induced diphasic dyskinesias in Parkinson's disease</title><author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Neurologie et Neuropsychologie and INSERM U 289, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bonnet, Anne Arie" sort="Bonnet, Anne Arie" uniqKey="Bonnet A" first="Anne-Marie" last="Bonnet">Anne-Marie Bonnet</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Neurologie et Neuropsychologie and INSERM U 289, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kefalos, John" sort="Kefalos, John" uniqKey="Kefalos J" first="John" last="Kefalos">John Kefalos</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Neurologie et Neuropsychologie and INSERM U 289, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Neurologie et Neuropsychologie and INSERM U 289, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Agid" sort="Agid" uniqKey="Agid" last="Agid">Agid</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Clinique de Neurologie et Neuropsychologie and INSERM U 289, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989">1989</date><biblScope unit="vol">4</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="195">195</biblScope><biblScope unit="page" to="201">201</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A0A1EF877A89AD91DC3BFBC1A4B1A1C73054D518</idno><idno type="DOI">10.1002/mds.870040301</idno><idno type="ArticleID">MDS870040301</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antagonist</term><term>Anticonvulsant</term><term>Benzodiazepine derivatives</term><term>Chemotherapy</term><term>Cholinergic receptor</term><term>Diazepam</term><term>Diazepam (therapeutic use)</term><term>Dopa</term><term>Drug interaction</term><term>Dyskinesia</term><term>Dyskinesias</term><term>Etybenzatropine</term><term>Human</term><term>Humans</term><term>Intramuscular administration</term><term>Intravenous administration</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Middle Aged</term><term>Movement Disorders (chemically induced)</term><term>Movement Disorders (drug therapy)</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's Disease</term><term>Pilot Projects</term><term>Prevention</term><term>Psychotropic</term><term>Toxicity</term><term>Treatment</term><term>Tropanes (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diazepam</term><term>Levodopa</term><term>Tropanes</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Middle Aged</term><term>Pilot Projects</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste</term><term>Anticonvulsivant</term><term>Benzodiazépine dérivé</term><term>Chimiothérapie</term><term>Diazépam</term><term>Dopa</term><term>Dyskinésie</term><term>Etybenzatropine</term><term>Homme</term><term>Interaction médicamenteuse</term><term>Parkinson maladie</term><term>Prévention</term><term>Psychotrope</term><term>Récepteur cholinergique</term><term>Système nerveux pathologie</term><term>Toxicité</term><term>Traitement</term><term>Voie intramusculaire</term><term>Voie intraveineuse</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa‐induced onset and end‐of‐dose dyskinesia are rare but disabling disorders. Although they can be attenuated by increasing and dividing the daily dose of levodopa, this does not constitute a therapeutic approach. In this pilot study, etybenzatropine, an anticholinergic drug, and diazepam, a selective benzodiazepine, were administered in addition to a single dose of levodopa in nine patients with Parkinson's disease. Both drugs tended to decrease the severity and the duration of onset and end‐of‐dose dyskinesia, and to increase the duration of action of levodopa on parkinsonian symptoms.</div></front></TEI><affiliations><list><country><li>France</li></country><settlement><li>Paris</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name></noRegion><name sortKey="Agid" sort="Agid" uniqKey="Agid" last="Agid">Agid</name><name sortKey="Bonnet, Anne Arie" sort="Bonnet, Anne Arie" uniqKey="Bonnet A" first="Anne-Marie" last="Bonnet">Anne-Marie Bonnet</name><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name><name sortKey="Kefalos, John" sort="Kefalos, John" uniqKey="Kefalos J" first="John" last="Kefalos">John Kefalos</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000670 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000670 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:A0A1EF877A89AD91DC3BFBC1A4B1A1C73054D518
|texte= Effects of etybenzatropine and diazepam on levodopa‐induced diphasic dyskinesias in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |